Can Overexpressing This Protein Combat Asthma?
"Research reveals RGS4's potential to alleviate airway hyper-responsiveness in mice, offering new therapeutic avenues for asthma."
Asthma, a chronic respiratory disease affecting millions worldwide, is characterized by airway hyper-responsiveness (AHR), leading to wheezing, dyspnea, and coughing. While inflammation and immune responses have been extensively studied, the contribution of airway smooth muscle (ASM) to AHR remains less understood. This is crucial because ASM contraction significantly narrows the airways, exacerbating breathing difficulties.
G protein-coupled receptors (GPCRs) on ASM cells play a key role in triggering airway constriction. When activated, these receptors initiate a cascade of intracellular events, ultimately leading to muscle contraction. However, this process is tightly regulated by a group of intracellular proteins known as Regulators of G protein Signaling (RGS).
RGS proteins, particularly the R4 subfamily including RGS4, have emerged as potential targets for asthma therapy. While previous studies have shown altered RGS4 expression in asthmatic patients, the direct impact of RGS4 overexpression on AHR has remained unclear. Now, a new study explores how RGS4 overexpression in the lungs impacts airway hyper-responsiveness, inflammation, and ASM contraction, offering a potential new approach to asthma management.
Current Asthma Mechanisms and RGS4
Asthma involves airway hyperresponsiveness (AHR), in which airway smooth muscle reacts excessively to environmental stimuli and contributes to intermittent, reversible airway obstruction. Many triggers activate G protein-coupled receptors (GPCRs) on airway smooth muscle cells. Research published April 1, 2024, reports that RGS4 interacts with the p85α subunit of PI3K and inhibits transforming growth factor beta-induced, PI3K-dependent PGE2 secretion in airway epithelial cells, suggesting that RGS4 may affect asthma severity by regulating the airway inflammatory environment through a G protein-independent mechanism.
From GPCRs to RGS4
GPCRs have a central role in asthma because they influence airway smooth muscle and airway inflammation. A 2012 study examined RGS4 in airway smooth muscle hyperplasia and the reduced contractile capacity associated with advanced asthma, including severe disease with bronchodilator- and steroid-insensitive airflow obstruction. More recent treatment paradigms have expanded from inhaled corticosteroids and beta-agonists to targeted add-on biologic therapies using monoclonal antibodies against specific mechanistic pathways.
RGS4: A Potential Game-Changer for Asthma?
Researchers investigated the effects of RGS4 overexpression in the lungs of transgenic mice. These mice were genetically engineered to express higher levels of RGS4, allowing scientists to observe the direct impact of this protein on airway function. The study focused on several key aspects:
- Reduced Airway Hyper-responsiveness (AHR): Transgenic mice with RGS4 overexpression exhibited reduced lung resistance when exposed to methacholine (MCh), indicating a protective effect against AHR.
- Diminished Contraction Signaling: RGS4 overexpression blunted the calcium mobilization and downstream effector activation in ASM cells, suggesting a direct impact on contraction signaling.
- Altered Inflammatory Response: The allergic inflammation was slightly reduced by RGS4 overexpression. The levels of IL-5 and IL-13 were significantly reduced in transgenic mice.
RGS4 and Airway Contractility
Recent research connects airway hyperresponsiveness with dysregulated GPCR signaling in airway smooth muscle. A review reports that dysfunction involving RGS2, RGS4, and RGS5 can mediate AHR without airway inflammation, apparently through enhanced GPCR-induced calcium influx and myosin light-chain phosphorylation. Another review emphasizes that modulating contractile and relaxation signaling is important for reducing AHR, while research in obese asthmatic mice found that the GPCR40-targeting compound DC260126 alleviated obese asthma in association with reduced GTP-RhoA and ROCK1.
RGS4 Expression Across Disease Severity
RGS4 is a cytoplasmic protein expressed in airway smooth muscle and bronchial epithelium that regulates GPCR activity. In the reported comparison, RGS4 immunoreactivity was much more extensive in the bronchial epithelium of lung samples from people with asthma than in samples from healthy controls. The extent of epithelial coverage increased proportionally with disease severity, and control lung sections showed no immunostaining with rabbit IgG or anti-rabbit IgG controls.
Future Directions and Therapeutic Potential
These findings open up exciting possibilities for new asthma therapies. While no current drugs directly increase RGS4 activity, researchers are exploring mechanisms to modulate RGS4 levels in the lungs. One potential strategy involves targeting the ubiquitin-proteasome pathway, which regulates RGS4 degradation.
Targeted and Technology-Enabled Treatment
A 2026 review of evidence published between 2020 and 2025 identifies three connected areas in emerging asthma therapy: targeted treatments across asthma endotypes, improved drug delivery to increase pulmonary deposition and therapeutic efficiency, and technology-enabled tools for adherence and disease management. Another 2025 review discusses deficiencies of current corticosteroid treatments alongside treatment mechanisms and new and emerging therapies. These directions suggest that future asthma care will involve both more precisely targeted interventions and efforts to improve how treatments reach the lungs and are used.
Severe Asthma and Airway Remodeling
Severe asthma can involve bronchodilator- and steroid-insensitive airflow obstruction, with increased airway smooth muscle mass and stiffness. The 2012 study of RGS4 examined its relationship to airway smooth muscle hyperplasia and the reduced contractile capacity characteristic of advanced asthma. It assessed RGS4 expression using immunocytochemical staining in endobronchial biopsies from healthy subjects and people with mild, moderate, and severe asthma.
By inhibiting the proteasome, scientists may be able to increase RGS4 levels and reduce AHR in asthmatic patients. However, further research is needed to determine the safety and efficacy of this approach. Future studies may also focus on developing drugs that specifically target RGS4 activity without affecting other proteins.
While congenital RGS4 overexpression is a limitation of the study, the research provides a first proof-of-concept evidence that increasing RGS4 levels in the lung can protect against AHR induced by acute allergen challenge. With further research, RGS4-based therapies may offer a new hope for individuals struggling with asthma and other respiratory conditions.